Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD97: a dedifferentiation marker in human thyroid carcinomas

G Aust1, W Eichler, S Laue

  • 1Department of Internal Medicine III, University of Leipzig, Germany.

Cancer Research
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Angiotensin converting enzymes ACE and ACE2 in thyroid cancer progression.

Neoplasma·2019
Same author

[Definition of R1 resection in thyroid carcinoma].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2017
Same author

[Preoperative genetic diagnostics and imaging for pediatric pheochromocytoma and paraganglioma].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2017
Same author

[Complications after thyroid gland operations in Germany : Further information and routine data analysis].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2017
Same author

[Secondary hyperparathyroidism after gastric bypass].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2017
Same author

[Julius Springer Prize for Surgery 2017 awarded].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2017

CD97, a cell surface molecule, is newly found in thyroid tissue. Its expression increases with thyroid cancer progression and may indicate dedifferentiation and lymph node involvement.

Area of Science:

  • Molecular Biology
  • Oncology
  • Immunology

Background:

  • CD97 is a transmembrane glycoprotein primarily found on hematopoietic cells.
  • Its expression outside the hematopoietic system has not been previously reported.
  • Thyroid carcinomas represent a significant area of oncological research.

Purpose of the Study:

  • To investigate the expression of CD97 in normal and neoplastic human thyroid tissue.
  • To determine the correlation between CD97 expression and thyroid tumor differentiation and staging.
  • To analyze CD97 expression in thyroid carcinoma cell lines.

Main Methods:

  • Immunohistochemical staining of normal thyroid tissue and thyroid carcinomas.
  • Analysis of CD97 expression in anaplastic and papillary thyroid carcinoma cell lines.

Related Experiment Videos

  • Quantification of cell surface CD97 levels and mRNA expression via RT-PCR.
  • Treatment with phorbol 12-myristate 13-acetate to study CD97 regulation.

    • Main Results:

    • CD97 was absent in normal thyroid tissue but showed low or absent expression in differentiated thyroid carcinomas.
    • High CD97 expression was observed in undifferentiated anaplastic carcinomas and correlated with advanced tumor stages (T1 to T4).
    • Thyroid carcinoma cell lines exhibited significantly higher CD97 expression compared to normal thyrocytes.
    • Phorbol 12-myristate 13-acetate treatment reduced CD97 expression, suggesting internalization.

    Conclusions:

    • CD97 is expressed in human thyroid neoplasms, particularly in anaplastic carcinomas.
    • CD97 expression levels correlate with tumor dedifferentiation and advanced stages.
    • CD97 may serve as a potential biomarker for thyroid tumor dedifferentiation and lymph node metastasis.